Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-05-08, Stock:ABBV, The news for the past five days is as follows:
2018-05-01: NEWS1: Why Nutrisystem, Tenet Healthcare, and AbbVie Jumped Today.NEWS2: Why Nutrisystem, Tenet Healthcare, and AbbVie Jumped Today.NEWS3: Seagate, Pfizer and Cummins skid while AbbVie jumps.NEWS4: Why Nutrisystem, Tenet Healthcare, and AbbVie Jumped Today.NEWS5: AbbVie’s Hepatitis C Franchise, Kaletra, and Synagis in 1Q18.NEWS6: MARKETS: Stocks are selling off on the ISM miss, which also reveals problems in the factory sector.NEWS7: AbbVie’s Humira and Imbruvica: 1Q18 Performance.NEWS8: How AbbVie Fared in 1Q18.NEWS9: How AbbVie Makes its Money.NEWS10: Pre-Market Most Active for May 1, 2018 :  BP, TVIX, QQQ, SNE, SHOP, AAPL, ABBV, UAA, KLXI, UA, AVXS, SQQQ.NEWS11: Pre-Market Most Active for May 1, 2018 :  BP, TVIX, QQQ, SNE, SHOP, AAPL, ABBV, UAA, KLXI, UA, AVXS, SQQQ.NEWS12: AbbVie Submits Marketing Authorization Application to the European Medicines Agency for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis.NEWS13: AbbVie Commences Self-Tender Offer for Up to $7.5 Billion of its Common Stock.NEWS14: [$$] Gilead shares rattled by sharp slide in hepatitis C drug sales.
2018-05-02: NEWS1: Seattle Genetics Accelerates Revenue Growth, Earnings Not So Much.NEWS2: Seattle Genetics Accelerates Revenue Growth, Earnings Not So Much.NEWS3: &quot;Fast Money&quot; final trades: SNAP, SPOT and more.NEWS4: Top 4 Marijuana Stocks to Watch.NEWS5: 9 Winning Stocks as the Bull Loses Steam.NEWS6: Gilead (GILD) Q1 Earnings & Sales Miss Estimates on Weak HCV.NEWS7: Gilead (GILD) Q1 Earnings & Sales Miss Estimates on Weak HCV.NEWS8: Analyst Recommendations for AbbVie in April.NEWS9: AbbVie to Present at the 2018 Bank of America Merrill Lynch Health Care Conference.NEWS10: Better Buy: Johnson & Johnson (JNJ) vs. AbbVie (ABBV).NEWS11: Better Buy: Johnson & Johnson (JNJ) vs. AbbVie (ABBV).NEWS12: Better Buy: Johnson & Johnson (JNJ) vs. AbbVie (ABBV).NEWS13: Gilead Sciences&apos; First-Quarter Twist: Weak HIV Sales.
2018-05-03: NEWS1: Top 5 Biotech Stocks for 2018.NEWS2: Did Gilead Sciences Make a Big Mistake?.NEWS3: Did Gilead Sciences Make a Big Mistake?.NEWS4: Did Gilead Sciences Make a Big Mistake?.NEWS5: NBIX: Strong INGREZZA® Sales Continue in 1Q18; Expanding Sales Team for Future Growth.NEWS6: Drugmakers eye a new threat to sales but say it hasn’t affected them — yet.NEWS7: Drugmakers eye a new threat to sales but say it hasn’t affected them — yet.NEWS8: Your first trade for Thursday, May 3.NEWS9: Your first trade for Thursday, May 3.
2018-05-04: NEWS1: 3 Value Stocks for Income Investors.NEWS2: 3 Value Stocks for Income Investors.NEWS3: Pharma Stock Roundup: Mixed Q1 for MRK, PFE, FDA Nod for Kymriah&apos;s 2nd Indication.NEWS4: Is Gilead Sciences Stock Finally a Bargain?.NEWS5: Is Gilead Sciences Stock Finally a Bargain?.NEWS6: Is Gilead Sciences Stock Finally a Bargain?.NEWS7: Gilead Sciences, Inc. Stock Will Recover… Eventually.NEWS8: Gilead Sciences, Inc. Stock Will Recover… Eventually.
2018-05-07: NEWS1: How Amgen’s Enbrel and Neulasta Performed in 1Q18.NEWS2: Taltz: Therapy for Psoriasis Indication.NEWS3: Allergan’s US General Medicines Segment in 1Q18.

Answer: Decrease